Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
IMNM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.97 - $30.96
Previous CloseN/A
Volume79.27K
Average Volume (3M)1.03M
Market Cap
$840.82M
Enterprise Value$642.79M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Mar 26, 2025EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.12
Shares Outstanding84,674,910
10 Day Avg. Volume955,063
30 Day Avg. Volume1,031,198
Standard Deviation0.41
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)61.19
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-72.17
Enterprise Value/Ebitda-5.70
Forecast
1Y Price Target
$23.00Price Target Upside127.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Immunome News
PremiumCompany Announcements
Immunome CFO Relocation and Compensation Package Unveiled
PremiumCompany Announcements
Immunome, Inc. Reports Q3 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Phase II DataIMNM presented positive updated Ph 2 data from the RINGSIDE study of AL102, its gamma secretase inhibitor, in patients with desmoid tumors.
Preclinical DevelopmentIMNM named three new ADCs in preclinical development and disclosed that the IND for IM-1021 was cleared ahead of the original guidance.
Bears Say
Competitive ChallengeThe median time to response for Ogsiveo was 5.6 months, which AL102 has to try to improve upon by offering a more rapid time to response, or deeper responses, or both.
---
Ownership Overview
1.46% Insiders
16.80% Mutual Funds
27.34% Other Institutional Investors
46.33% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $8.97 and its highest was $30.96 in the past 12 months.
What is Immunome’s market cap?
Immunome’s market cap is $840.82M.
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is Mar 26, 2025 which is in 32 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Nov 13, 2024. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.551 by -$0.229.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -0.67.
How many shares outstanding does Immunome have?
Immunome has 84,674,910 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.551. Following the earnings report the stock price went down -3.883%.
Which hedge fund is a major shareholder of Immunome?
Currently, no hedge funds are holding shares in IMNM
---
Immunome Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.00 (127.50% Upside)
$23.00 (127.50% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.68%
12-Months-Change
Fundamentals
Return on Equity
-276.36%
Trailing 12-Months
Asset Growth
175.76%
Trailing 12-Months
Company Description
Immunome
Immunome Inc is a biopharmaceutical company engaged in the discovery and development of novel antibody-based drugs. The company's proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. It is developing treatments for treating cancer and other infectious diseases.
---
IMNM Stock 12 Month Forecast
Average Price Target
$23.00
▲(127.50% Upside)
Technical Analysis
Best Analysts Covering IMNM
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-35.20%
reiterated a buy rating last month
Copying Andrew Berens's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -35.20% per trade.
---